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Abstract
Background: Supported by the International Society for Translational Medicine (ISTM), Wenzhou Medical College
and the First Affiliated Hospital of Wenzhou Medical College, the International Conference on Translational
Medicine (ICTM) was held on October 22–23, 2011 in Wenzhou, China. Nearly 800 registrants attended the meeting,
primarily representing institutes and hospitals in Europe, The United States of America, And Asia, and China. The
meeting was chaired and organized by Dr. Xiangdong Wang, Xiaoming Chen, Richard Coico, Jeffrey M. Drazen,
Richard Horton, Francesco M. Marincola, Laurentiu M. Popescu, Jia Qu and Aamir Shahzad.
Findings: The meeting focused on the communication of the need to foster translational medicine (TM) by
building and broadening bridges between basic research and clinical studies at the international level. The meeting
included distinguished TM experts from academia, the pharmaceutical and diagnostics industries, government
agencies, regulators, and clinicians and provided the opportunity to identify shared interests and efforts for
collaborative approaches utilizing cutting edge technologies, innovative approaches and novel therapeutic
interventions. The meeting defined the concept of TM in its two-way operational scheme and emphasized the
need for bed to bench efforts based directly on clinical observation.
Conclusions: It was the meeting participants’ realization that the shared main goals of TM include breaking the
separation between clinic practice and basic research, establishing positive feedback by understanding the basis of
expected and unexpected clinical outcomes and accelerating basic research relevant to human suffering. The
primary objectives of the meeting were two-fold: to accelerate the two-way translation by informing the
participants representing the different disciplines about the state of art activities around TM approaches; and to
identify areas that need to be supported by redirecting limited resources as well as identifying new sources of
funding. This report summarizes key concepts presented during the meeting representing the state-of-art
translational research and salient aspects of the ensuing discussions.
Keyword: Translational Medicine (TM), International Society for Translational Medicine (ISTM), the International
Conference on Translational Medicine (ICTM), Biomarkers, Biobank globalization and networking
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Introduction
It is becoming increasingly clear from the current state
of the science that Translational Medicine (TM) should
increase its international efforts. Advances in technology
and medicine produced an unprecedented wealth of data
which extends our understanding of human biology to a
completely new dimension. Placing these data into use-
ful context for developing better clinical practice is com-
plicated by the sheer size of datasets being generated
and the limited set of tools for translating this informa-
tion into useful products such as biomarkers, targets for
therapeutic intervention, and safe and effective drugs
or diagnostic compounds. In the last decade much
resource has been dedicated to providing useful biomar-
kers that can aid in clinical decision making and patient
management.
However, among the numerous biomarkers identified,
only a few have undergone extensive validation. In the
same fashion, drug discovery is facing an even less
rewarding reality as few originally promising products
eventually pass the standards demanded for approval
after long clinical trials. Meanwhile, disease mortality
and morbidity have barely changed over the years, other
than that which results from early screening programs
that support early detection and intervention. Thus, the
efforts and resources consumed on the generation of ex-
perimental data has been disproportional to the obtained
results aimed at the improvement of patient suffering. It
is clear that while current technologies have almost
limitless potential, barriers such as inadequate study
design, limited standardization and cross-validation
among laboratories, suboptimal comparability of data,
missing globalized efforts and inefficient utilization of
limited resources remain major road blocks. The institu-
tion of an interactive consortium for a globalized
biorepository, high throughput and multidimensional
technologies, sophisticated experimental and clinical
study design, strong bioinformatics approaches, and
harmonization of studies through the implementation of
standard operative procedures with voluntary participa-
tion might provide cost-effective solutions.
The Evolution of Translational Medicine (TM)
Dr. Richard Coico, Ph.D., Professor of Cell Biology and
Medicine, State University of New York-Downstate
Medical Center, Brooklyn, NY pointed out that although
TM is considered an emerging new field, in reality, ele-
ments of it have been practiced for millennia. Its evolu-
tion can be traced back to ancient Egypt (c. 2600 BC)
when philosophers serving as clinicians, observed and
promoted the use of various dietary and topical remedies
for disease (e.g. fruits, linseed oil). They were also the
first to demonstrate the antiseptic properties of Willow
leaves and bark. These and many other examples of the
successful translation of simple observations into useful
clinical applications demonstrate how rudimentary heal-
ing practices became the standard of care. In the middle
ages, Avicenna (c. 1030) wrote The Canon of Medicine
which established, for the first time, the legitimacy of ex-
perimental medicine and the importance of evidence-
based medicine. The Canon was used as a standard text-
book in Muslim and European universities until the 18
th
century. During the same period, discovery of the thera-
peutic utility of digitalis in treating heart disease was
made by the English botanist and physician, William
Withering, ushering in what is considered the beginning
of modern therapeutics. These and countless other
translational medicine benchmarks in the 18
th-early 20
th
centuries were obtained long before the tools of molecu-
lar biology, computational biology, genomics, proteo-
mics, etc. and the rules of ethical treatment of human
subjects for research, animal welfare, and bio-safety were
available. The complexity of translating observations to
clinical applications has progressively increased through-
out the centuries due to ethical and practical concerns.
However, the goals remain the same. The ancestral
achievements in medical understanding will need to be
matched in the 21st century by exploiting new and novel
technologies, and by improving study design and coord-
inating cross-discipline activities which, in ancient times,
would have been considered magical.
Translational medicine-the paradigm shift
Dr. Francesco M. Marincola, Editor-in-Chief of the Jour-
nal of Translational Medicine, President Elect of ISTM
and vice-President of SITC, Chief of the Infectious Dis-
ease and Immuongenetics Section (IDIS), Department of
Transfusion Medicine (DTM), Clinical Center (CC), Na-
tional Institutes of Health (NIH) has been a strong advo-
cate for translational medicine for the last decade. He
echoed that the TM is not a novel concept and has many
different definitions with the same intention. However,
TM emphasizes the modern need to increase the effi-
ciency of the process over various hurdles that hamper
the translation from oberservation to clinical testing.
Fewer than 5% of new agents tested in clinical trials
reach regulatory approval and less than 1% will turn into
successful products [1-3]. Therefore, the novelty of TM
lays on redirecting funding resources to accelerate the
transition by catalyzing research relevant to humans for
the ultimate benefit of patients. It has been almost a
decade since he suggested that translational medicine is
a two-way road where the predominant emphasis on the
bench-to-bedside direction should be balanced by the
bedside-to-bench one. He proposed that attention to
clinical relevance should play a leading role in framing
scientific questions according to human actuality. He
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careful observation of events relevant to human diseases.
Such observations should be based on skillful studies
performed in human subjects, at relevant time points
and at the site where the patho-physiological process
and its perturbation induced by treatment is evolving.
Translational research is caught in a vicious cycle
whereby: 1. the enterprise is based on a less than solid
understanding of human pathophysiology particularly
when complex, multi-factorial diseases are confronted;
2. scientists “hypothesize” based on individual experi-
ences as to relevance to human disease based on the
comfort zone of their knowledge rather than an in depth
understanding of human disease; 3. pre-clinical models
are generated, which are, in turn, poor predictors of ef-
fectiveness in humans because they do not take into ac-
count the salient aspect of human pathophysiology and
its fundamentally unpredictable nature. Hence, only by
identifying, from thousands of hypotheses, the patho-
physiological common themes that actually occur in
humans, scientists will be likely to develop therapeutic
strategies likely to work in most if not all patients.
Dr. Michael N. Liebman, Managing Director, Strategic
Medicine, Inc. (PA, USA), discussed the issues of stratifi-
cation and personalization in medicine within the con-
text of translational medicine. He clarified conceptual
differences among translational, personalized and strati-
fied medicine. In agreement with Dr. Marincola, TM
should not only start in the lab and expect to translate
results into the clinic but the bedside-to-bench-to-bed-
side approach should be implemented. TM has focused
more on the transition from basic research to clinical
use while personalized medicine and stratified medicine
have focused on stratifying the patient utilizing genetic
markers to tailor individual treatments for specific
groups of patients. His emphasis was on examining the
stratification of the disease, not just the patient,, and that
although genetics may determine an individual’s poten-
tial benefit from treatment, it is critical to include life-
time influences of environmental exposure and lifestyle
experiences which modulate the impact of genetics, both
positively and negatively. He advocated that human dis-
ease is not a state as we frequently refer to “disease
state” but rather a process which is complicated by nu-
merous factors such as genetic predisposition, acquired
predispositions to disease, co-morbidity, length of dis-
ease since diagnosis, treatment history, diverse response
to a given therapy and other yet unspecified modifiers.
Integration and research into the role of those factors
will likely yield greater success in improving patient care
and developing new diagnostics and treatments than the
ongoing development of the new technologies which are
constantly being introduced to improve speed and effi-
ciency in both basic research and the developmental
phase of drug development. Therefore, disease stratifica-
tion must be based on information derived from an
expanded personal health record for the patient, along
with the use of advanced technology, and comprehensive
clinic testing followed by the development and applica-
tion of sophisticated data mining and bioinformatics
analysis [4]. He presented examples of breast cancer pa-
tient stratification by a modeling approach whereby can-
cer patients were stratified according to histology, tumor
progression pattern, TNM staging normalized according
to peri-menopausal to post menopausal status. This ap-
proach included pathway and network analysis based on
regulation of gene transcription and genetic polymorph-
ism. He also summarized hurdles confronting clinical in-
vestigation that include high cost, non standardized
patient selection criteria, and inadequate comprehensive
clinical information before enrollment and inadequate
hypothesis development.
International effort in TM
Dr. Jia Qu, School of Ophthalmology and Optometry,
Wenzhou Medical College, China, summarized world-
wide efforts in TM evidenced by the launch of Clinical
and Translation Research Centers in more than 30 med-
ical colleges, the establishment of Clinical and Transla-
tional Science Awards and the National Center for
Advancing Translational Sciences (NCATS) with $575
million Government funding at NIH in the United
States. In Europe, 6 billion Euros has invested for trans-
lational research. UK will spend 450 million pounds to
build translation medicine centers within the next
5 years. However, TM in China is challenged by limited
financial support, relative weak support from basic re-
search and a publication-focused system rather than
aimed at patient benefit. Based on his success in transla-
tion from the research development of optical coherence
tomography (OCT) to ophthalmic medicine application,
he proposed that team work and broad collaboration is
essential for advance and success in TM.
As the awareness and excitement of applying transla-
tional medicine increase worldwide, journals and articles
focused on TM or related to TM are proportionally
swelling accordingly. Dr. Jeffrey M. Drazen, Editor-in-
Chief of the New England Journal of Medicine exempli-
fied journal publication process and its sensitivity to
translational science emphasizing that the decision mak-
ing in the selection of manuscripts for publication is
based predominantly on their influence on clinic prac-
tice. In 2010, more than 25% of original research articles
published by the NEJM had a translational scope. There
were a significant number of submissions from China in
2010, but only minorities of the submitted manuscripts
were accepted for publication due to either substandard
scientific quality or poor writing due to language issues.
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aim for high impact publications by giving several exam-
ples of recently published manuscripts adopting well-
designed study strategies addressing high impact clinical
question. Dr Drazen welcomed inquiries from perspective
submitters to ask for advice from the Editorial Office
prior to submission. He also highlighted several new
methods in journalism that are being launched to in-
clude electronic media, such as videos of research studies
presented as stories, and for the need to make scientific
advancements more easily understood within society.
Complexity of translational research
Fundamental strides in the understanding of the mo-
lecular basis of disease have been made in the last dec-
ade thanks to observational studies performed at
relevant time points in humans. The advance of technol-
ogy and their application revealed the complexity of
human biology in pathophysiological conditions. Dr. Ena
Wang, Director of Molecular Sciences, Department of
Transfusion Medicine, Clinical Center, and Associated
Director, trans-NIH Center for Human Immunology,
National Institutes of Health illustrated the impact of
genetic polymorphisms, global transcriptional regulation,
epigenetic regulation, environmental influence and pre-
existing conditions in the interpretation of human biol-
ogy. She proposed that a system biology approach with
multidimensional analysis including all possible variants
should be considered when dissecting human pathology.
The low yield of relevant information derived from clin-
ical studies results mainly from the insufficient clinical
and patient information collection, minimal stratification
of variables contributing to a given condition, biased se-
lection of patient population and non standardized re-
search procedures. She presented examples of using
system biology to study the significance of transcrip-
tional signatures observed in pre-treatment biopsies as
predictive of responsiveness to immune therapy. By
comparing transcriptional signatures observable during
and after immune therapy a convergent characterization
from chronic to acute inflammation switch was
observed. The switch not only can lead to tumor rejec-
tion but more in general to all forms of immune-
mediated tissue destruction processes including flares of
autoimmunity, clearance of pathogen-infected cells, allo-
graft rejection and graft versus host disease. This obser-
vation suggests that each model system has its own
idiosyncrasies but, at the same time, commonalities dic-
tate the final outcome of rejection. Understanding of the
basic mechanisms of tissue rejection may guide the de-
velopment of novel therapeutic strategies. Even more
importantly, identifying the mechanisms that lead to this
final common pathway in individual tumors may define
a better rational for targeted therapies. These are good
examples of evidence-based clinically relevant research
that has generated hypotheses that could now be pur-
sued at the bench side.
Biomarker discovery
Biomarkers comprise a very broad concept. The term
biomarker usually refers to any biological measurement
that provides information regarding disease progression,
relationship with treatment, safety and can be used for
decision making in clinical or experimental applications.
Depending upon the source, time, condition and pos-
sible application, biomarkers can be categorized into 1)
translational biomarkers: a biomarker that can be ap-
plied in both a preclinical and clinical setting; 2) disease
biomarkers: biomarkers that relate to a clinical outcome
or measure of disease; 3) efficacy biomarkers: a bio-
marker that reflects beneficial effect of a given treat-
ment; 4) staging biomarkers: a biomarker that
distinguishes between different stages of a chronic dis-
order; 5) surrogate biomarkers: a biomarker that is
regarded as a valid substitute for a clinical outcomes
measure; 6) toxicity/safety biomarkers: a biomarker that
reports a toxicological effect of a drug on an in vitro or
in vivo system; 7) mechanistic biomarkers: a biomarker
that reports activity downstream of signaling pathway;
and 8) target biomarkers: a biomarker that reports inter-
action of the drug with its target. Dr. Xiangdong Wang,
Professor of Medicine and Molecular Bioscience, Dir-
ector of the Biomedical Research Center, Fudan Univer-
sity Zhongshan Hospital, China, presented strategies in
biomarker discovery with different objectives in clinic
application and in biomedical research. Irrespective the
great strides being made in biomarker identification,
there are as yet unmet needs in developing standards
and guidelines that define toxicology, clinical phenotyp-
ing, , dosage decision making, treatment attrition deci-
sions, and patient stratification. There are also pressing
needs to improve in early disease diagnosis, health care
system management and integration, new drug effect
validation, medical instrumentation, and diagnostic tests
that comply with regulatory standards. Dr Wang also
emphasized that clinical bioinformatics that provided
systematic information associated with patients has been
under appreciated and is one key step towards transla-
tional research.
Definition of “healthy status”
One critical premise of disease-related biomarkers is the
definition of their counterpart, normality. Contrary to
pre-clinical models that can be carefully tailored to meet
scientific need and preferred outcomes, the essence of
human disease involves heterogeneity in clinical presen-
tation and with a complex biological basis that is not
easily controlled for all possible models of behavior in a
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consistent parameters that can define the predicted be-
havior of disease processes developing in previously
healthy subjects is as yet not attainable. Self proclaimed
normal status may not represent health because asymp-
tomatic subjects may carry chronic diseases or diseases
at their early stage such as seen in many cancer types.
Professor Wei Wang, MD, PhD, from Edith Cowan Uni-
versity, Perth, Australia, Chinese Academy of Sciences
and Capital Medical University, Beijing, China, and Pro-
fessor Toshio Fujioka MD, PhD from Oita University,
Oita, Japan exemplified the characterization of the sub-
optimal health status (SHS) which represents a new pub-
lic health problem in a population with ambiguous
health complaints such as general weakness. They ap-
plied clinical informatics approaches and developed a
questionnaire for measuring SHS. The validity and reli-
ability of this approach were evaluated in a small pilot
study and then in a cross-sectional study of 3,000 indivi-
duals. The final questionnaire segregated into a score
(SHSQ-25) which could significantly several abnormal
conditions and could be used in the general population
[5-7].
Epigenetic biomarkers
Epigenetic interactions occur at many levels and result
in changes in the genome by a variety of mechanisms
that are driven by including transcriptomic, metabolo-
mic or proteomic interactions that play a major role in
determining phenotypes beyond genetic background.
Among epigenetic components, micro RNA (miR), func-
tions as regulatory RNA target transcripts that lead to
protein translation inhibition or messenger RNA degrad-
ation. Variable expression of miRs has been associated
with diverse vascular diseases [8-11]. Recent studies have
demonstrated that miRNAs are aberrantly expressed in
proliferative vascular disease, cardiac hypertrophy, heart
failure, and ischemic heart disease. Chunxiang (Kevin)
Zhang MD, PhD, Director of RNA& Cardiovascular Re-
search Laboratory, and Vice Chairman for Research at
Department of Anesthesiology, New Jersey Medical
School, UMDNJ described his work on miR function in
association with Cardiovascular Diseases. By miR array
profiling, his group observed that miR-145 is highly
expressed in normal arteries but aberrantly expressed in
stenotic arteries in experimental animal model and as
well as in human atherosclerotic aortas with neointimal
growth. Based on the observation that abundant release
of miR-1 from necrotic cardiac myocytes following acute
myocardial infarction in animal model, they identified
that miR-1 levels increase 100 times following AMI in
humans. Therefore, miR-1 could be a potentially novel
diagnostic marker for AMI patient.
Dr. William CS Cho, , PhD, CSci, FIBMS, Chief Editor
of Frontiers in Non-Coding RNA, Department of Clinical
Oncology, Queen Elizabeth Hospital, Hong Kong SAR
studied miRs as biomarkers in lung cancer. He discov-
ered that miR-145 plays an important role in inhibiting
lung cancer proliferation by targeting EGFR and
NUDT1. Restoring miR-145 expression in vitro in EGFR
mutated lung cancer cell line could significantly reduce
cell proliferation. In patients with NSCLC, EGFR muta-
tions are strongly associated with EGFR-tyrosine kinase
inhibitors (TKI) sensitivity. This finding suggests that it
may be possible to individualize EGFR-TKI treatment
for lung adenocarcinoma patients based on EGFR muta-
tion [12]. However, miR may represent promising mar-
kers, their application in the clinics is challenged by
tissue biopsies accessibility. As an alternative, the identi-
fication of circulating miRNAs may represent a valuable
strategy for noninvasive early diagnosis and follow-up
investigations [13].
Protein biomarkers
Protein biomarkers have been used clinically as a stan-
dardized laboratory reference to diagnose and differenti-
ate the status of both health and disease. These
measurements play a significant role in clinical decision
making, both as comparators with normal ranges and
activities and as monitors of dysfunctional physiologic
and metabolic processes in cells located in specific organ
systems [14]. Prof. Thomas Fehniger, Institute of Clinical
Medicine, Tallinn University of Technology, Tallinn, Es-
tonia, exemplified the importance of protein structure
and function in relation to human health and disease.
He emphasized the importance of linking panels of dis-
ease related biomarkers with histopathological changes
observed in diseased tissues.
Clinical proteomics is an important component of
TM. However, protein biomarker discovery is challenged
by detection sensitivity and low abundance of many
functional proteins involved in disease processes. Intra-
cellular protein content exhibits 9-orders of magnitude
in range of concentration. Depending on specific protein
abundance, the required number of cells to detect a
given substrate can range from 6e3 cell with 1e6 copy of
protein to 6e8 cell with 10 copy of protein. As a result,
proteins discovered by the HUPO’s plasma proteome
project are largely distributed in the concentration above
ug/ml range while clinically used biomarkers are mainly
in ng to pg range [15]. Therefore, identifying proteins in
the right context remains an important obstacle to over-
come. He brought attention to the fact that in the
current status, there is a gap between proteomic bio-
marker discovery and their quantification. He urged the
need for well characterized patients and samples for bio-
marker discovery; the need to establish reference
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ation in population based studies in global settings.
To overcome the low abundance of functional protein,
Aamir Shahzad, MD, Editor in chief, Translational Bio-
medicine Journal (TBM), University of Vienna, Austria
applied fluorescence correlation spectroscopy (FCS) to
study interactions among bio-molecules expressed at ex-
tremely low-concentration in solution. FCS was able to
measure diffusion time and the average number of fluor-
escent molecules passing through the open detection in
1ul volume. The technology can detect proteins directly
without incubation nor enzymatic reaction and allows
the study of complex formation between a small fluores-
cently labeled and a large unlabeled molecule. In
addition of the sensitivity and reproducibility, the test
results can be obtained in 15 min which make it a po-
tential tool for clinical application.
Post-translational modifications (PTM) are a major
challenge in protein biomarker identification. Reversible
protein phosphorylation, an important type of cellular
regulation, controls many biological processes such as cell
growth, differentiation, invasion, metastasis and apoptosis.
Abnormal protein phosphorylation can be the cause or
consequence of many diseases such as cancer. The de-
regulation of protein kinase activity with its consequent
change in protein phosphorylation states has been asso-
ciated with the onset of tumor formation and cancer pro-
gression. The importance of protein kinase-regulated
signal transduction pathways in human cancer has led to
the development of drugs that inhibit protein kinases at
the apex or intermediary levels of these pathways. Phos-
phoproteomic analysis of these signaling pathways could
provide important insights into the operation and con-
nectivity of these pathways and can facilitate the identifi-
cation of the best targets for cancer therapies. Elena
López, PhD from Hospital Universitario12 de Octubre,
Spain, updated the current phosphoproteomic approaches
by comparing advanced strategies. Though no standard
procedure has been established, Dr. López proposed that
the combination of multi-stage collision-induced dissoci-
ation (CID) fragmentation, the development of electron
transfer dissociation (ETD) and electron capture ECD
fragmentation of peptides in mass spectrometry (MS) with
phosphor-enrichments may be the method of choice to
study protein post-translational modifications. MS-based
phosphor-proteomics tools are critical to understand the
structure and dynamics of signaling that engages and
migrates through the entire proteome. These PTMs ultim-
ately give rise to the emergent functions of cells in se-
quence, space and time. She also summarized various
approaches used for the analysis of the phosphor-
proteome in general and protein kinases in particular,
highlighting key cancer phosphor-proteomic studies. Dif-
ferent proteomic and bioinformatics strategies need to be
combined to achieve good phosphor-peptide quantitative-
protein studies. From the point of view of the so-called
“personalized medicine”, bioinformatics studies of rever-
sible phosphorylation in proteins will allow the generation
of models for protein-protein interaction at the atomic
level taking into account each particular protein sequence.
Molecular dynamic analysis of those interactions will
allow the modification of the 3D computer models obtain-
ing virtual structures tailored to individual patients
[16-18].
Pre-clinical Studies
Several pre-clinical models were presented as examples
of bench-to-bed efforts. It is well known that pulmonary
arterial hypertension (PAH) is a prevalent disease with a
high mortality rate, and often afflicts patients with
chronic obstructive pulmonary disease (COPD) and
other chronic lung diseases as well as high altitude resi-
dents due to chronic hypoxic cellular responses. How-
ever, the molecular mechanisms underlying PAH remain
unclear, and current therapeutic options remain limited.
Yong-Xiao Wang from the Center of Cardiovascular
Sciences, Albany Medical College, Albany, New York,
USA described the role of ryanodine receptors/calcium
release channels (RyRs) in pulmonary artery smooth
muscle cells (PASMCs) in the development of hypoxic
PAH. He reported that RyR activity, associated calcium
release and contraction were largely increased in
PASMCs from mice with hypoxic PAH. The increased
activity of RyRs was confirmed in PASMCs from COPD
patients with PAH. Pharmacological and genetic block-
ade of RyRs almost completely prevented hypoxic PAH
in mice. These exciting results provide the first evidence
that RyR calcium signaling plays an essential role in the
development of hypoxic PAH, and also suggest RyR
antagonists that are available and even used in clinic
may become potentially new and effective therapeutics
to treat PAH and other relevant pulmonary vascular dis-
eases in the future.
To explore the mechanism of acute lung injury,
Hongwei Gao, Center for Experimental Therapeutics
and Reperfusion Injury, Brigham and Women's Hospital,
Department of Anesthesiology, Perioperative & Pain
Medicine, Harvard Medical School, Boston, described
how Stat3 is activated in alveolar macrophages and
whole lung extracts in the IgG immune complex-
induced lung injury model. This could be dramatically
suppressed by blockade of C5a in the lung or depletion
of either neutrophils or alveolar macrophages. Treat-
ment of mice with an adenoviral vector expressing a
dominant-negative Stat3 isoform (Ad-Stat3-EVA) elimi-
nated IgG immune complex-induced DNA binding ac-
tivity of Stat3 in the lung and led to a significant
decrease in the contents of neutrophils, inflammatory
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MIP-1β), and complement component C5a in bronch-
oalveolar lavage fluids compared with control. This sug-
gested that Ad-Stat3-EVA might affect neutrophil
adhesion to the lung vascular endothelium and/or their
subsequent transmigration by modulation of adhesion
pathway(s).
Gene-environment interactions in pathogenesis
In the past decade, great effort has been made to explore
the genetic background of humans and its association
with disease. This effort led to the completion of Human
Genome Project and the Hapmap project. Ongoing inter-
national efforts include the Cancer Genome Atlas, genetic
association information network, genome wide associ-
ation, gene and environment initiative, and the 1000 gen-
ome study. Linkage analysis of single nucleotide
polymorphism and whole genome-wide association has
been applied to the study of specific diseases which has
increased our understanding of the contribution of genet-
ics to pathogenesis. Genetic polymorphisms are the basis
of diverse human phenotypes, disease susceptibility, prog-
nosis and responsiveness to treatment. Though genetic
traits play a pivotal role, they could be influenced by envir-
onment factors. Markus Ege, MD MPH, University of
Munich, Germany Children’s Hospital, Munich, Germany
gave an example of gene and environment interactions in
asthma and allergy. Polymorphisms of a number of genes
have been consistently related to asthma [19,20]. These
genes are involved in pathways of the innate and adaptive
immunity and in epithelial barrier functions [20]. How-
ever, among children who carry the identified polymorph-
isms, only a minority developed asthma. Paradoxically,
asthmatics can carry a low genetic asthma risk while
healthy individuals can carry high genetic asthma risk.
Those cases of asthma occurring without a genetic predis-
position could be due to environmental exposures related
to asthma such as tobacco smoking [21]. A trend was
documented of increased prevalence of asthma is in areas
of high industrialization and pollution. As the isolated as-
sessment of genetic and environmental determinants can-
not explain causation of asthma alone, he hypothesized
that the enhancement of genetic predisposition by envir-
onmental determinants might provide a better explan-
ation. His group applied comprehensive assessment of
gene/environment interactions using a genome wide ap-
proach with a statistical method that controls for multiple
testing [22]. Despite adequate statistical power only few
weak novel interactions were detected suggesting that
gene/environment interactions might be even more com-
plex and should be sought at different levels comprising
global gene expression and analysis of epigenetic modifi-
cations. Alternatively the genetic and environmental
effects in this population were so strong that they did not
modify each other.
Notwithstanding the importance of environmental fac-
tors in asthma, David C. Christiani, MD, MPH,MS Elkan
Blout Professor of Environmental Genetics Harvard
School of Public Health, Massachusetts General Hos-
pital, Boston, Massachusetts, furthered his study in how
genetics and environment interact to increase lung can-
cer risk. Susceptibility of lung cancer at different time
points along the natural history of an individual depends
on many factors such as exposure to smoking, dose of
smoking, lung structure and function alteration and dis-
ease progression. He reported how his group investi-
gated how DNA repair function gene variants interact
with smoking to increase lung cancer risk. Among those
genes, ERCC2 Asp312Asn, XRCC1 Arg399Gln, ERCC1
C8092 genotype shows a significant impact from years
of smoking, going from protective to non-protective as
indicated by inversed correlation of adjusted odds ratio
and pack-years of smoking. A genome wide association
scan (GWAS) conducted by multi centers identified a
susceptible locus (15q25) for lung cancer [23] which
accounts only for 4% of lung cancer risk. To interrogate
whether variants on the 15q25.1 region affect lung can-
cer through nicotine dependence and are associated with
smoking or through other pathways, they applied novel
methodology for analysis of 1836 lung cancer patients
and 1452 controls and found evidence of an effect
mediated through smoking. In addition, a positive cor-
relation between cumulative cigarette smoking and CNV
were observed which provides insight into the genetic
toxicology of tobacco smoke. Therefore, Dr. Christiani
concluded that common diseases such as lung cancer
likely result from genetic and environmental distur-
bances in entire networks of genes rather than in a sin-
gle, or even a several genes.
Application of translational medicine
Stroke is one of the leading causes of mortality and dis-
ability in the world. Stroke survivors are often left with
permanent neurological deficit resulting from the loss of
neurons, which severely impacts their quality of life.
From 1955–2000, 49 neuro-protective agents for stroke
therapy have been tested in 21,445 patients. However,
none of the tested agents were approved for clinical ap-
plication [24]. Current treatment options are limited. Dr.
Kunlin Jin, Tenured Professor at the Department of
Pharmacology and Neuroscience, University of North
Texas Health Science Center at Fort Worth, Texas,
USA, presented recent advances in stem cell-based ther-
apy for chronic stroke. His group and others have shown
in animal models that neural precursor cells trans-
planted into effected regions of the brain can differen-
tiate into neurons, and have the potential to improve
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brain tissue in the infarction cavity after stroke, they ap-
plied tissue engineering approaches using neural stem
cells in scaffolds grafted in the cavity. This is based on
the hypothesis that the scaffolds may not only provide
the necessary biomechanical support for cells, guide the
gross shape and size of the regenerated tissue into form-
ing three-dimensional tissues, but also provide artificial
stem cell niches necessary for stem cell growth. Add-
itionally, scaffolds can serve as biochemical signals that
influence cell adhesion, migration, proliferation, differen-
tiation and functions. His group successfully experimen-
ted with in situ tissue engineering using a combination
of injectable and biodegradable scaffolds and hESC-
derived neural stem cells to mouse brain cavity caused
by experimental stroke. This result suggests that this ap-
proach has great potential as a powerful new therapy for
stroke in human.
Prof Xiaokun Li Phd, School of Pharmacy, Wenzhou
Medical College described how fibroblast growth factors
(FGF) plays a critical role in cell division, development
and wound healing via activation of growth factor recep-
tor and initiation of a downstream cascade of signal
transduction, and gene activation. Experimental data
have shown that a single amino acid substitution at pos-
ition 78 and 96 of the protein [25]or N-terminal removal
[26] makes the mutated FGF more stable without
impacting its biological function. PEGylation modifica-
tion of the recombinant FGF21 makes it not only stable
but long lasting as an anti-diabetic drug [27,28] and a
promising drug for wound healing according to animal
models. With a chitosan-cross-linked collagen sponge
(CCCS) as scaffold that contains recombinant human
aFGF (CCCS/FGF), accelerated diabetic wound healing
and corneal epithelial wound healing were observed. An
FGF analog (aFGF) is being tested in a phase II clinical
trial that is suggesting significant improvement of dia-
betes wound healing and burn healing. Products were
derived from this study including bFGF eye drop
(Cornea recover), membrane, gel, freeze-dry powder, col-
lagen sponge and spray for clinical use.
Professor Lawrence M. Popescu, Department of Advanced
Studies, National Institute of Pathology, Bucharest, Romania,
presented the discovery and characterization of inter-
stitial cells – Telocytes (TCs) which have been found
in cavitary and non-cavitary organs of humans and
mammalians. TCs have a small cell body with specific
prolongations named telopodes (Tps). TCs can modify
neighbor cells transcriptional activity by shedding vesi-
cles and/or exosomes facilitating precursor cells towards
maturation and their integration into the microscopic
architecture of tissues. This function is supported by
the experimental observation that TC are directly and
indirectly involved in neo-angiogenesis after myocardial
infarction suggesting a possible application in regenera-
tive medicine.
The need for guidelines and standardization
The past decade, basic research has decoded numerous
unknown entities relevant to biology and accelerated our
understanding of physiology and pathology. There are
far more basic researchers and publications based on
in vitro or experimental models which are more easily
controllable and as a consequence more easily funded
and published. However, among candidate drugs suc-
cessfully tested in animals, very few withstand the exten-
sion to humans due to fundamental differences in
genetic makeup of humans, their heterogeneity and the
heterogeneity of their diseases and the impact of the eas-
ily controllable genetics within inbred animals. There is
also a high level of complexity and diversity in human
genetic and genomic compositions that produce biology
that cannot be modeled experimentally or foreseen in
the results generated in animal studies. It is important to
emphasize that TM should foster bed-to-bench effort to
provide better understanding of human pathology and
understanding the reasons for failure of current standard
or experimental therapies. The first step toward study
humans is to collect samples which preserve the max-
imum in vivo information and can be used by diverse
yet available cutting edge technologies.
Dr. György Marko-Varga, European Editor of the Jour-
nal of Proteome Research, ACS, and President of The
European Proteomics Society (www.EuPA.org), Division
of Clinical Protein Science & Imaging, Biomedical Cen-
ter, Dept. of Measurement Technology and Industrial
Electrical Engineering, Lund University, Sweden, urged
the great importance of the establishment of a global
biobank to speed up the discovery and development of
new drugs and protein biomarker diagnostics. Biobanks
are providing patient benefit by allowing large scale
screening and generating large database repositories.
Biobanks are a major resource for scientists to access
unique patient samples for medical research. Many stud-
ies within clinical proteomics utilize stored samples con-
tained in Biobanks to measure specific end points. It is
envisioned by all participating stakeholders and ICTM
participants that the biobank initiatives will become the
future gateway to discover new frontiers within life sci-
ence, patient care and catalyzing the two way road of
TM [29]. Biobank globalization and networking by com-
bining and sharing precious samples and information
associated with the sample can empower large joint
studies to tackle major biological question with limited
resources and eliminate less meaningful small repetitive
study due to the complexity of human biology and het-
erogeneity of patients. Standardization of quality control
of samples being processed for storage as well as
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support the development of diagnostic tools such as bio-
markers. Today we have not yet achieved consensus on
how to collect, manage, and build biobank archives in
order to reach goals where these efforts are translated
into value for the patient.
Effort in developing guidelines for more effective and
safe therapy should also be enhanced. Dr. Claudio
Spada, MISM Science & Technology Consulting -
SCConsulting, Milan, Italy pointed out that Guidelines
developed in 2002 required significant changes based on
new information and advances in medicine. He updated,
in 2007, the guidelines for treatment of sepsis compared
with 2002 guidelines. As new developments in diagnosis
and promising therapies tested in animals and humans
will emerge, they will need to be validated in large clin-
ical trials to confirm the safety and efficacy of their use
in septic patients.
Roland Andersson, MD, PhD from Department of Sur-
gery, Clinical Sciences, Lund University Hospital, Swe-
den updated the epidemiology and available therapy for
pancreatic cancer. He discussed the challenges in lack of
biomarkers for early diagnosis and prognosis [30], al-
though this field has been actively explored. Numerous
therapeutic agents and antibodies have been developed
targeting IGF-1R, EGRR and VEGFR signaling pathways
with intention to block cancer cell proliferation, angio-
genesis or revert drug resistance [31,32]. The improved
survival of pancreatic patients has not significantly
encouraged broader investigation of tumor biology facili-
tated by microenvironment. In the improvement of early
diagnosis of pancreatic cancer, proteomic application
using serum/plasma has revealed over expression of
Alpha-1B-glycoprotein precursor, Anterior gradient 2,
Apolipoprotein C-I, DJ-1, Fibrinogen β chain, HSP27
and under expression of Apolipoprotein A-II, Caldecrin,
CXCL7. Dr. Andersson pointed out that although a
multitude of investigational biomarkers have been iden-
tified; translating into routine clinical use has been slow.
It was realized that standardization in analysis techni-
ques and better reporting will improve the translation of
biomarkers. New guidelines for diagnostic biomarkers
[33] and for prognostic markers (REporting recommen-
dations for tumor MARKer prognostic studies [34] are
available and should be followed closely.
Mass spectrometry imaging
Dr. György Marko-Varga, gave a presentation on a new
technology area where it is possible to localize a drug
compound with a resolving power within a single cell.
Readouts that define the physiological distributions of
drugs in tissues are an unmet challenge and at best
imprecise. It is also needed in order to understand both
the pharmacokinetic and pharmacodynamic properties
associated with efficacy. Drug therapy is often directed
to specific organ and tissue compartments where the
mode of action of the compound affects specifically tar-
geted biological processes. However, the direct measure-
ment of drug uptake in terms of a time kinetic and
concentrations attained at the local sites has not been
readily available as a clinical index for most drugs. It is
feasible to follow the unlabeled drugs within specific
organ and tissue compartments on a platform that ap-
plies MALDI imaging mass spectrometry to tissue sec-
tions characterized with high definition histology.
Moreover, the simultaneous global definition of molecu-
lar ion signatures localized within 2-D tissue space pro-
vides accurate assignment of ion identities within
histological landmarks, providing context to dynamic
biological processes occurring at sites of drug presence.
He reported on a recently performed proof-of-principle
study that tested the power of applying MALDI-MSI to
demonstrate the qualitative drug distribution of inhaled
bronchodilators in COPD patients. The study mapped
the occurrence of the muscarinic receptor antagonist
ipratropium, within human bronchial biopsies obtained
by fiber optic bronchoscopy shortly after dosing
exposure. This is the first reported study in man, at a
resolving power of 30 μm, of drug localization within
organ microenvironments using normal clinical dosing
schemes and standardized laboratory measurement [35].
He also emphasized that MALDI-MSI approaches will
play an increasingly important role in both drug
development in the optimization of compounds and in
clinical efficacy testing.
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